Clinical Trial Update: A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC [Phase 1]

View source ↗

Summary

An ongoing Phase 1 (Phase Ib) clinical trial is evaluating REGN5678 in combination with cemiplimab for metastatic castration-resistant prostate cancer and is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• REGN5678

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | Phase 1 | Status: RECRUITING